Shares of A-Mark Precious Metals (AMRK) have gained 13.8% over the past four weeks to close the last trading session at $26.65, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $40.5 indicates a potential upside of 52%.The average comprises four short-term price targets ranging from a low of $29.00 to a high of $63.00, with a standard deviation of $15.8. While the lowest estimate ...

Core Viewpoint - Phathom Pharmaceuticals, Inc. (PHAT) has shown a significant price increase of 21% over the past four weeks, with a mean price target of $20.5 indicating an upside potential of 87.2% from the current price of $10.95 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $8.02, indicating variability among analysts [2] - The lowest estimate is $5.00, suggesting a potential decline of 54.3%, while the highest estimate is $29.00, indicating a potential increase of 164.8% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 4.2%, with one estimate moving higher and no negative revisions [12] - PHAT currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after by investors, they can mislead more often than guide, and should not be the sole basis for investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Brainsway Ltd. Sponsored ADR (BWAY) shares have increased by 7.4% over the past four weeks, closing at $12.98, with a mean price target of $16.3 indicating a potential upside of 25.6% [1] - The mean estimate consists of four short-term price targets with a standard deviation of $2.15, where the lowest estimate is $14.20 (9.4% increase) and the highest is $19.00 (46.4% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 11.5% over the last 30 days [11][12] Group 2 - BWAY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Group 1 - MongoDB (MDB) shares have increased by 10.5% over the past four weeks, closing at $209.2, with a mean price target of $280.88 indicating a potential upside of 34.3% [1] - The mean estimate is based on 33 short-term price targets with a standard deviation of $54.3, where the lowest estimate is $170.00 (indicating an 18.7% decline) and the highest is $430.00 (indicating a 105.5% increase) [2] - Analysts show strong agreement on MDB's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - Over the last 30 days, 11 earnings estimates for MDB have been revised higher, with no negative revisions, leading to a 15.8% increase in the Zacks Consensus Estimate [12] - MDB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - Kimbell Royalty (KRP) shows potential for further upside, with a mean price target of $18.6 indicating a 27.3% upside from its current price of $14.61, following an 11.7% gain over the past four weeks [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $4.98, indicating variability among analysts; the lowest estimate is $12.00 (17.9% decline), while the highest is $24.00 (64.3% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, although it does not guarantee the stock will reach the average target [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about KRP's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 34.1%, with one estimate moving higher and no negative revisions [12] - KRP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can mislead; empirical research shows that they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Oric Pharmaceuticals, Inc. (ORIC) has seen a significant stock price increase of 44.1% over the past four weeks, closing at $8.17, with analysts suggesting a potential upside to a mean price target of $18.90, indicating a 131.3% increase from the current price [1] Price Targets and Analyst Consensus - The average price target from analysts ranges from a low of $12 to a high of $25, with a standard deviation of $4.04, suggesting a potential increase of 46.9% to 206% from the current price level [2] - A low standard deviation indicates a strong agreement among analysts regarding the price targets, which can be a useful indicator for further research [2][9] Earnings Estimates and Market Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, five estimates for ORIC have increased, leading to a 12.6% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - ORIC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Group 1 - Shares of Triple Flag Precious Metals (TFPM) have increased by 6.4% over the past four weeks, closing at $21.56, with a mean price target of $27.07 indicating a potential upside of 25.6% [1] - The average of 11 short-term price targets ranges from a low of $19 to a high of $36, with a standard deviation of $5.47, suggesting variability in analyst estimates [2] - Analysts show a consensus that TFPM will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for TFPM has increased by 1.3% due to three upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - TFPM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Core Viewpoint - ACM Research, Inc. (ACMR) has seen a 2.6% increase in share price over the past four weeks, closing at $27.50, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $35.14, representing a 27.8% upside [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $3.39, where the lowest estimate of $31 indicates a 12.7% increase, and the highest estimate suggests a 45.5% surge to $40 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [7] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about ACMR's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, one estimate has increased, leading to a 40.4% rise in the Zacks Consensus Estimate for the current year [10] - ACMR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [11] Caution on Price Targets - While consensus price targets are often sought after, they may not reliably indicate actual stock price movements, and investors should approach them with skepticism [5][8]